Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Results of Operations and Financial Condition

Arbutus Biopharma Corporation (NASDAQ:ABUS) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On January 13, 2020, Arbutus Biopharma Corporation (the “Company”) disclosed in an updated corporate presentation that its unaudited cash position as of December 31, 2019 was $90.8 million. Included in the Company’s unaudited cash position as of December 31, 2019 was approximately $18.9 million of net proceeds from the sale of the Company’s common stock under its at-the-market offering program made throughout the year ended December 31, 2019.
Item 8.01. Other Events.
On January 13, 2020, the Company posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Arbutus Biopharma Corp Exhibit
EX-99.1 2 corporatepresentationjan.htm EXHIBIT 99.1 corporatepresentationjan Singularly Focused on HBV January 2020 NASDAQ: ABUS www.arbutusbio.com   Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include,…
To view the full exhibit click here

Story continues below

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

An ad to help with our costs